# GLSI (Greenwich Lifesciences, Inc.) - SEC EDGAR Financial Statements

> Greenwich Lifesciences, Inc. reported $5.90M in total assets and a net loss of $24.57M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/GLSI
- Markdown: https://convexityos.com/fundamentals/GLSI.md
- SEC CIK: 0001799788
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:43 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001799788&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$24.78M | Operating profit |
| Net Income | FY 2025 | -$24.57M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$1.67 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $5.90M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $17.22M | $15.48M | $7.70M | $6.48M | $3.56M | $1.06M | $2.61M |
| Total Operating Expenses | $19.45M | $17.64M | $9.33M | $8.04M | $4.60M | $1.86M | $3.43M |
| **Operating Income** | -$19.45M | -$17.64M | -$9.33M | -$8.04M | -$4.60M | -$1.86M | -$3.43M |
| Interest Income | $90K | $223K | $436K | $215K | $27K | $832 | -- |
| **Net Income** | -$19.36M | -$17.41M | -$8.89M | -$7.83M | -$4.57M | -$1.86M | -$3.43M |
| Basic EPS | -$1.43 | -$1.34 | -$0.69 | -$0.61 | -$0.35 | -$0.20 | -$1.52 |
| **Diluted EPS** | -$1.43 | -$1.34 | -$0.69 | -$0.61 | -$0.35 | -$0.20 | -$1.52 |
| Basic Shares Outstanding | 13.5M | 13.0M | 12.8M | -- | 12.9M | 9.5M | 2.3M |
| Diluted Shares Outstanding | 13.5M | 13.0M | 12.8M | 12.9M | 12.9M | 9.5M | 2.3M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $5.45M | $3.56M | $5.21M | $8.27M | $3.27M | $3.42M | $2.27M | $8.69M |
| Total Operating Expenses | $5.86M | $4.02M | $5.73M | $9.18M | $3.73M | $3.77M | $2.77M | $9.71M |
| **Operating Income** | -$5.86M | -$4.02M | -$5.73M | -$9.18M | -$3.73M | -$3.77M | -$2.77M | -$9.71M |
| Interest Income | $47K | $73K | $69K | $22K | $23K | $21K | $24K | $44K |
| **Net Income** | -$5.81M | -$3.95M | -$5.66M | -$9.15M | -$3.71M | -$3.75M | -$2.74M | -$9.67M |
| Basic EPS | -$0.40 | -$0.27 | -$0.39 | -- | -$0.27 | -$0.28 | -$0.21 | -- |
| **Diluted EPS** | -$0.40 | -$0.27 | -$0.39 | -- | -$0.27 | -$0.28 | -$0.21 | -- |
| Basic Shares Outstanding | 14.7M | 14.6M | 14.6M | -- | 13.6M | 13.4M | 13.2M | -- |
| Diluted Shares Outstanding | 14.7M | 14.6M | 14.6M | -- | 13.6M | 13.4M | 13.2M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $6.18M | $4.09M | $6.99M | $13.47M | $27.20M | $28.66M | $6.8K |
| **Cash & Short-Term Investments** | $6.18M | $4.09M | $6.99M | $13.47M | $27.20M | $28.66M | $6.8K |
| **Total Current Assets** | $6.18M | $4.09M | -- | -- | -- | $28.66M | $6.8K |
| Intangible Assets | -- | $1.8K | $5.4K | $9.0K | $13K | $16K | $20K |
| **Total Non-Current Assets** | $0 | $1.8K | -- | -- | -- | $16K | $20K |
| **Total Assets** | $6.18M | $4.09M | $6.99M | $13.48M | $27.22M | $28.68M | $27K |
| Accounts Payable | $4.65M | $1.18M | $35K | -- | -- | -- | -- |
| **Total Current Liabilities** | $5.82M | $3.19M | $294K | $263K | $385K | $1.05M | $1.38M |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Total Liabilities** | $5.82M | $3.19M | $294K | $263K | $385K | $1.05M | $1.38M |
| Common Stock | $14K | $13K | $13K | $13K | $13K | $13K | $8.5K |
| Retained Earnings | -$87.14M | -$67.78M | -$50.36M | -$41.47M | -$33.65M | -$29.08M | -$27.21M |
| **Total Stockholders' Equity** | $353K | $909K | $6.70M | $13.21M | $26.83M | $27.63M | -$1.35M |
| Total Equity | $353K | $909K | $6.70M | $13.21M | $26.83M | $27.63M | -$1.35M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $5.90M | $8.88M | $10.51M | $6.18M | $3.81M | $3.13M | $2.75M | $4.09M |
| **Cash & Short-Term Investments** | $5.90M | $8.88M | $10.51M | $6.18M | $3.81M | $3.13M | $2.75M | $4.09M |
| **Total Current Assets** | $5.90M | $8.88M | $10.51M | $6.18M | -- | -- | -- | $4.09M |
| Intangible Assets | -- | -- | -- | -- | -- | -- | $876 | $1.8K |
| **Total Non-Current Assets** | $0 | $0 | $0 | $0 | -- | -- | -- | $1.8K |
| **Total Assets** | $5.90M | $8.88M | $10.51M | $6.18M | $3.81M | $3.13M | $2.75M | $4.09M |
| Accounts Payable | $6.68M | $4.81M | $4.29M | $4.65M | -- | -- | $1.05M | $1.18M |
| **Total Current Liabilities** | $7.65M | $5.76M | $5.24M | $5.82M | $1.62M | $1.69M | $1.44M | $3.19M |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $0 | $395K | $835K | $1.11M | $0 |
| **Total Liabilities** | $7.65M | $5.76M | $5.24M | $5.82M | $2.02M | $2.52M | $2.55M | $3.19M |
| Common Stock | $15K | $15K | $15K | $14K | $14K | $13K | $13K | $13K |
| Retained Earnings | -$102.6M | -$96.74M | -$92.79M | -$87.14M | -$77.59M | -$73.44M | -$69.41M | -$67.78M |
| **Total Stockholders' Equity** | -$1.75M | $3.12M | $5.27M | $353K | $1.79M | $604K | $200K | $909K |
| Total Equity | -$1.75M | $3.12M | $5.27M | $353K | $1.79M | $604K | $200K | $909K |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$19.36M | -$17.41M | -$8.89M | -$7.83M | -$4.57M | -$1.86M | -$3.43M |
| Stock-Based Compensation | $6.80M | $7.25M | $2.38M | $1.74M | $661K | $678K | $195K |
| Change in Payables | $2.07M | $2.55M | $35K | -- | -$527K | -$93K | $393K |
| **Operating Cash Flow** | -$9.91M | -$7.27M | -$6.48M | -$6.20M | -$4.29M | -$1.15M | -$293K |
| Common Stock Issued | -- | -- | -- | -- | $3.11M | $30.17M | -- |
| Share Repurchases | -- | -- | -- | -$7.54M | -- | -- | -- |
| **Financing Cash Flow** | $12.00M | $4.37M | -- | -$7.54M | $2.84M | $29.81M | $215K |
| **Net Change in Cash** | $2.09M | -$2.90M | -$6.48M | -$13.74M | -$1.46M | $28.65M | -$78K |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$5.81M | -$3.95M | -$5.66M | -$9.15M | -$3.71M | -$3.75M | -$2.74M | -$9.67M |
| Stock-Based Compensation | $950K | $1.48M | $1.54M | $2.17M | $1.54M | $1.54M | $1.54M | $5.47M |
| Change in Payables | $1.87M | $519K | -$365K | $3.37M | -$628K | -$28K | -$643K | $2.03M |
| **Operating Cash Flow** | -$2.98M | -$1.94M | -$4.70M | -$3.17M | -$2.67M | -$2.23M | -$1.83M | -$1.85M |
| **Financing Cash Flow** | $0 | $311K | $9.03M | $5.55M | $3.35M | $2.61M | $492K | $122K |
| **Net Change in Cash** | -$2.98M | -$1.63M | $4.33M | $2.37M | $682K | $375K | -$1.34M | -$1.73M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -5480.5% | -1916.5% | -132.7% | -59.2% | -17.0% | -6.7% | -- |
| Return on Assets (ROA) | -313.3% | -425.4% | -127.1% | -58.1% | -16.8% | -6.5% | -12842.8% |
| Current Ratio | 1.06x | 1.28x | -- | -- | -- | 27.41x | 0.00x |
| Quick Ratio | 1.06x | 1.28x | 23.74x | 51.23x | 70.63x | 27.41x | 0.00x |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -- | -720.9% | -422.6% | -5480.5% | -1109.8% | -3115.6% | -8821.6% | -1916.5% |
| Return on Assets (ROA) | -416.6% | -253.2% | -212.0% | -313.3% | -521.9% | -602.5% | -642.9% | -425.4% |
| Current Ratio | 0.77x | 1.54x | 2.01x | 1.06x | -- | -- | -- | 1.28x |
| Quick Ratio | 0.77x | 1.54x | 2.01x | 1.06x | 2.35x | 1.85x | 1.91x | 1.28x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
